-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson Reports CARVYKTI Achieves 80% Treatment-Free Remission at 2.5 Years in Multiple Myeloma Trial

Reuters·12/06/2025 14:30:25

Please log in to view news